Full history for every metric is available with a Kvantra account
Myovant Sciences Ltd. (MYOV)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 59 | 231 | 379 |
| Operating profit | $m | -187 | -147 | |||||
| Net profit | $m | -83 | -143 | -274 | -289 | -255 | -206 | -184 |
| EPS reported | $ | -2.22 | -1.91 | |||||
| Operating cashflow per share | $ | -2.89 | -2.89 | |||||
| Capex per share | $ | 0.01 | 0.01 | |||||
| FCF per share | $ | -2.90 | -2.90 | |||||
| Free cash flow | $m | -270 | -271 | |||||
| Net debt | $m | -66 | 84 | |||||
| Book value equity | $m | -473 | -558 | |||||
| Book value per share | $ | -5.09 | -5.76 | |||||
| Number of shares | m | 92.98 | 96.86 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -2.62 | -4.70 | |||||
| P/S LTM | x | 5.36 | 6.92 | |||||
| P/FCF LTM | x | -4.59 | -9.69 | |||||
| EV/EBITDA LTM | x | -6.52 | -19.29 | |||||
| EV/Sales LTM | x | 5.19 | 7.14 | |||||
| Earnings Yield LTM | % | -16.63% | -8.21% | |||||
| FCF Yield | % | -21.76% | -10.32% | |||||
| Quality | ||||||||
| ROE | % | 43.50% | 49.79% | |||||
| ROIC | % | -68.92% | -68.92% | |||||
| Operating margin | % | -81.11% | -81.11% | |||||
| Gross margin | % | 77.68% | 77.68% | |||||
| FCF/Sales | % | -116.70% | -116.70% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +289.39% | +91.46% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.73 | -0.74 | |||||
| Net Debt/EBITDA | x | 0.21 | 0.21 | |||||
| EBIT/Net interest | x | -13.41 | -13.41 | |||||
| Net debt/market cap | % | -5.35% | 3.21% | |||||
| Net debt/Equity | x | 0.14 | -0.15 | |||||
| Gross debt/equity | x | -0.78 | -0.66 | |||||
Company overview
Myovant Sciences Ltd. is a biopharmaceutical company focused on innovating healthcare solutions for both women and men. Its flagship product is relugolix, an orally administered, once-daily small molecule that functions as a gonadotropin-releasing hormone (GnRH) receptor antagonist. This medication is indicated for conditions such as heavy menstrual bleeding caused by uterine fibroids, pain associated with endometriosis, and advanced prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin agonist, currently in Phase II clinical trials for treating female infertility within assisted reproductive procedures. Myovant collaborates with Pfizer Inc. for the development and commercialization of relugolix across oncology and women's health sectors. Incorporated in 2016, initially as Roivant Endocrinology Ltd. before rebranding to Myovant Sciences Ltd. in May of that year, the firm is based in London, United Kingdom, and operates as a subsidiary of Sumitovant Biopharma Ltd.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Myovant Sciences Ltd. (MYOV)
Myovant Sciences Ltd. is a biopharmaceutical company focused on innovating healthcare solutions for both women and men. Its flagship product is relugolix, an orally administered, once-daily small molecule that functions as a gonadotropin-releasing hormone (GnRH) receptor antagonist. This medication is indicated for conditions such as heavy menstrual bleeding caused by uterine fibroids, pain associated with endometriosis, and advanced prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin agonist, currently in Phase II clinical trials for treating female infertility within assisted reproductive procedures. Myovant collaborates with Pfizer Inc. for the development and commercialization of relugolix across oncology and women's health sectors. Incorporated in 2016, initially as Roivant Endocrinology Ltd. before rebranding to Myovant Sciences Ltd. in May of that year, the firm is based in London, United Kingdom, and operates as a subsidiary of Sumitovant Biopharma Ltd.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free